title: Circulating 25-Hydroxyvitamin D and Prostate Cancer Survival.
abstract: Recent epidemiologic evidence suggests that higher circulating vitamin D does not protect against prostate cancer and, in fact, may increase the risk of developing this malignancy. However, few studies have examined the most clinically relevant outcome, prostate cancer mortality.
  
  
  
  We examined prediagnostic serum 25-hydroxy-vitamin D (25(OH)D) and prostate cancer survival in a cohort of 1,000 cases in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study. During 23 years of follow-up, 363 men died from their disease. Cox proportional hazards models were used to estimate the hazard ratio (HR) and 95% confidence interval (CI) of death from prostate cancer by season-specific quintile of 25(OH)D. Multivariable models were adjusted for age, physical activity, cigarettes per day, and family history of prostate cancer.
  
  
  
  Men with higher serum 25(OH)D were less likely to die from their prostate cancer (Q5 vs. Q1 HR, 0.72; 95% CI, 0.52-0.99; Ptrend = 0.006). This finding was independent of stage or grade at diagnosis and appeared restricted to men who survived longer (survived <3.3 years: Q5 vs. Q1 HR, 0.95; 95% CI, 0.61-1.50; Ptrend, 0.53; survived ≥3.3 years: Q5 vs. Q1 HR, 0.53; 95% CI, 0.34-0.85; Ptrend, 0.0002).
  
  
  
  In this population of men diagnosed with prostate cancer, higher serum 25(OH)D years prior to diagnosis was associated with longer prostate cancer survival.
  
  
  
  In light of inconsistent evidence regarding the role of vitamin D in the development of prostate cancer, the present findings regarding the most clinically relevant prostate cancer outcome, disease-specific mortality, could have important public health implications. Cancer Epidemiol Biomarkers Prev; 25(4); 665-9. ©2016 AACR.
authors.affiliation: Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, NIH, Bethesda, Maryland. Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan. amondul@umich.edu.
authors.forename: Alison M
authors.initials: AM
authors.lastname: Mondul
authors.affiliation: Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, NIH, Bethesda, Maryland.
authors.forename: Stephanie J
authors.initials: SJ
authors.lastname: Weinstein
authors.affiliation: Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, NIH, Bethesda, Maryland.
authors.forename: Kristin A
authors.initials: KA
authors.lastname: Moy
authors.affiliation: Department of Health, National Institute for Health and Welfare, Helsinki, Finland.
authors.forename: Satu
authors.initials: S
authors.lastname: Männistö
authors.affiliation: Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, NIH, Bethesda, Maryland.
authors.forename: Demetrius
authors.initials: D
authors.lastname: Albanes
mesh_terms: D000368:Aged; D004311:Double-Blind Method; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000453:epidemiology* / Q000401:mortality; D016019:Survival Analysis; D014807:Vitamin D / Q000031:analogs & derivatives* / Q000097:blood
chemical_list: D014807:Vitamin D; C104450:25-hydroxyvitamin D
references.citation: Clin Exp Metastasis. 2005;22(3):275-84
references.pmid: 16158255
references.citation: Ann Epidemiol. 2009 Feb;19(2):73-8
references.pmid: 18329892
references.citation: Br J Cancer. 2009 Feb 10;100(3):450-4
references.pmid: 19156140
references.citation: Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1929-33
references.pmid: 19454612
references.citation: Am J Epidemiol. 2010 Jul 1;172(1):10-20
references.pmid: 20562188
references.citation: Cancer Epidemiol Biomarkers Prev. 2011 Sep;20(9):1850-60
references.pmid: 21784952
references.citation: J Natl Cancer Inst. 2012 May 2;104(9):690-9
references.pmid: 22499501
references.citation: Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):688-96
references.pmid: 23377224
references.citation: Cancer Epidemiol. 2013 Oct;37(5):666-70
references.pmid: 23972671
references.citation: CA Cancer J Clin. 2014 Jul-Aug;64(4):252-71
references.pmid: 24890451
references.citation: Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1494-504
references.pmid: 24732629
references.citation: Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1484-93
references.pmid: 25085836
references.citation: J Cancer Res Clin Oncol. 2014 Sep;140(9):1465-77
references.pmid: 24838848
references.citation: PLoS One. 2015;10(3):e0119690
references.pmid: 25774530
references.citation: Cancer. 2015 Jun 15;121(12):1949-56
references.pmid: 25731953
references.citation: Am J Clin Nutr. 2004 Mar;79(3):362-71
references.pmid: 14985208
references.citation: Prostate. 2004 May 15;59(3):243-51
references.pmid: 15042599
references.citation: Clin Biochem. 2004 Oct;37(10):867-74
references.pmid: 15369717
references.citation: Am J Epidemiol. 1988 Sep;128(3):667-76
references.pmid: 2843041
references.citation: Anticancer Res. 1990 Sep-Oct;10(5A):1307-11
references.pmid: 2241107
references.citation: Ann Epidemiol. 1994 Jan;4(1):1-10
references.pmid: 8205268
references.citation: Cancer Epidemiol Biomarkers Prev. 1999 Mar;8(3):241-8
references.pmid: 10090302
references.citation: Cancer Causes Control. 2005 Mar;16(2):83-95
references.pmid: 15868450